Hiroaki Yasuda

Prof. Hiroaki Yasuda

Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science Kyoto Prefectural University of Medicine, Kajii-cho 465, Kamigyo-ku, Kyoto 602-8566, Japan
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2016 in Gut
Verified
Journal Article
Closed access
PDF file
Atsushi MasamuneAtsushi Masamune
Atsushi Masamune
INIsao Nishimori
Isao Nishimori
KKKazuhiro Kikuta
Kazuhiro Kikuta
ITIchiro Tsuji
Ichiro Tsuji
NMNobumasa Mizuno
Nobumasa Mizuno
TSTooru Shimosegawa
Tooru Shimosegawa
Objective Corticosteroid has been established as the standard therapy for autoimmune pancreatitis (AIP), but the requirement for maintenance corticosteroid therapy is controversial. We conducted a randomised controlled trial to clarify the efficacy of maintenance corticosteroid therapy in patients with AIP. Design We conducted a multicentre, tertiary setting, randomised controlled trial. After the induction of remission with the initial oral prednisolone (PSL) treatment, maintenance therapy with PSL at 5–7.5 mg/day was continued for 3 years or withdrawn at 26 weeks. The primary endpoint was relapse-free survival over 3 years and the secondary endpoint was serious corticosteroid-related complications. All analyses were performed on an intention-to-treat basis. Results Between April 2009 and March 2012, 49 patients with AIP were randomly assigned to the maintenance therapy group (n=30) or the cessation group (n=19). Baseline characteristics were not different between the two groups. Relapses occurred within 3 years in 11 out of 19 (57.9%) patients assigned to the cessation group, and in 7 of 30 (23.3%) patients in the maintenance therapy group. The relapse rate over 3 years was significantly lower in the maintenance therapy group than that in the cessation group (p=0.011). The relapse-free survival was significantly longer in the maintenance therapy group than that in the cessation group (p=0.007). No serious corticosteroid-related complications requiring discontinuation of PSL were observed. Conclusions Maintenance corticosteroid therapy for 3 years may decrease relapses in patients with AIP compared with those who discontinued the therapy at 26 weeks. Trial registration number UMIN000001818; Results.

4 January 2016 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
TITetsuhide Ito
Tetsuhide Ito
HIHiroshi Ishiguro
Hiroshi Ishiguro
HOHirotaka Ohara
Hirotaka Ohara
TKTerumi Kamisawa
Terumi Kamisawa
JSJunichi Sakagami
Junichi Sakagami
TSTooru Shimosegawa
Tooru Shimosegawa

30 October 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NINaoto Iwai
Naoto Iwai
TOTakashi Okuda
Takashi Okuda
JSJunichi Sakagami
Junichi Sakagami
THTaishi Harada
Taishi Harada
TOTomoya Ohara
Tomoya Ohara
YIYoshito Itoh
Yoshito Itoh
Inflammation-based prognostic indicators have been developed to predict the prognosis in patients with pancreatic cancer. However, prognostic indices have not been established in patients with unresectable pancreatic cancer, including those without indication for chemotherapy at diagnosis. This study aimed to identify the predictors in all patients with unresectable pancreatic cancer. We retrospectively analyzed data of 119 patients with unresectable pancreatic cancer from June 2006 to September 2018. The following laboratory parameters were evaluated: the Glasgow Prognostic Score (GPS), modified GPS, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein albumin (CRP/Alb) ratio, and prognostic nutritional index (PNI). We performed time-dependent receiver operating characteristic analysis, overall survival (OS) analysis, and univariate and multivariate analyses to determine the prognostic factors in patients with unresectable pancreatic cancer. The cut-off value for NLR was determined to be 3.74. The 6-month OS rates in low and high NLR groups were 75.5% and 18.8% (P < 0.001). In the univariate analysis, advanced age (P = 0.003), metastatic pancreatic cancer (P = 0.037), no treatment (P < 0.001), worse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) (P < 0.001), high GPS (P < 0.001), high modified GPS (P < 0.001), high NLR (P < 0.001), high PLR (P = 0.002), high CRP/Alb ratio (P < 0.001), and low PNI (P < 0.001) were identified as the prognostic factors. The multivariate analysis revealed that metastatic pancreatic cancer (P = 0.046), no treatment (P < 0.001), worse ECOG-PS (P = 0.002), and high NLR (P < 0.001) were independently associated with OS. We revealed that the high NLR could be an independent indicator of poor prognosis in patients with unresectable pancreatic cancer.

1 February 2020 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
AKAkira Kurita
Akira Kurita
SYSatoru Yasukawa
Satoru Yasukawa
YZYoh Zen
Yoh Zen
KYKenichi Yoshimura
Kenichi Yoshimura
TOTakeshi Ogura
Takeshi Ogura
SYShujiro Yazumi
Shujiro Yazumi

1 August 2005 in Laboratory Investigation
Verified
Journal Article
Closed access
KLKwang M Lee
Kwang M Lee
HYHiroaki Yasuda
Hiroaki Yasuda
MHMichael A Hollingsworth
Michael A Hollingsworth
MOMichel M Ouellette
Michel M Ouellette

28 February 2018 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
SNSumiyuki Nishida
Sumiyuki Nishida
TITakeshi Ishikawa
Takeshi Ishikawa
SEShinichi Egawa
Shinichi Egawa
SKShigeo Koido
Shigeo Koido
HYHiroaki Yanagimoto
Hiroaki Yanagimoto
HSHaruo Sugiyama
Haruo Sugiyama
We investigated the efficacy of a Wilms' tumor gene 1 (WT1) vaccine combined with gemcitabine (GEMWT1) and compared it with gemcitabine (GEM) monotherapy for advanced pancreatic ductal adenocarcinoma (PDAC) in a randomized phase II study. We randomly assigned HLA-A*02:01– or HLA-A*24:02–positive patients with advanced PDAC to receive GEMWT1 or GEM. We assessed WT1-specific immune responses via delayed-type hypersensitivity (DTH) to the WT1 peptide and a tetramer assay to detect WT1-specific cytotoxic T lymphocytes (WT1-CTL). Of 91 patients enrolled, 85 were evaluable (GEMWT1: n = 42; GEM: n = 43). GEMWT1 prolonged progression-free survival [PFS; hazard ratio (HR), 0.66; P = 0.084] and improved overall survival rate at 1 year (1-year OS%; GEMWT1: 35.7%; GEM: 20.9%). However, the difference in OS was not significant (HR: 0.82; P = 0.363). These effects were particularly evident in metastatic PDAC (PFS: HR 0.51, P = 0.0017; 1-year OS%: GEMWT1 27.3%; GEM 11.8%). The combination was well tolerated, with no unexpected serious adverse events. In patients with metastatic PDAC, PFS in the DTH-positive GEMWT1 group was significantly prolonged, with a better HR of 0.27 compared with the GEM group, whereas PFS in the DTH-negative GEMWT1 group was similar to that in the GEM group (HR 0.86; P = 0.001). DTH positivity was associated with an increase in WT1-CTLs induced by the WT1 vaccine. GEM plus the WT1 vaccine prolonged PFS and may improve 1-year OS% in advanced PDAC. These clinical effects were associated with the induction of WT1-specific immune responses. Cancer Immunol Res; 6(3); 320–31. ©2018 AACR.